Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.47 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | UGT2B7 | P16662 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | TDO2 | P48775 | 2/20 | 0.42 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.41 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.41 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.41 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL502826 | 1.00 | AOC3 (0.47) | AOC3NOS3NOS1UGT2B7IDO1 | |
| SCHEMBL57895 | 1.00 | AOC3 (0.47) | AOC3NOS3NOS1UGT2B7IDO1 | |
| SCHEMBL11620987 | 0.93 | PTPN5 (0.50) | AOC3NOS3NOS1UGT2B7IDO1 | |
| SCHEMBL11129545 | 0.87 | TRPA1 (0.40) | AOC3NOS3NOS1IDO1TDO2 | |
| SCHEMBL9331190 | 0.85 | NOS3 (0.54) | NOS3NOS1UGT2B7PTPN5HTT | |
| SCHEMBL9331652 | 0.85 | NOS3 (0.54) | NOS3NOS1UGT2B7PTPN5HTT | |
| SCHEMBL9331061 | 0.85 | NOS3 (0.54) | NOS3NOS1UGT2B7PTPN5HTT | |
| SCHEMBL40655 | 0.85 | NOS3 (0.54) | NOS3NOS1UGT2B7PTPN5HTT | |
| Piperidine SCHEMBL28981210 | 0.82 | SLC6A2 (0.41) | AOC3HTT | |
| SCHEMBL15450371 | 0.79 | AOC3 (0.48) | AOC3IDO1TDO2HDAC3HDAC4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104262095-A | R-1-(4-fluorophenyl)ethanol and synthesis of ester thereof | WANG TONGJUN | 2015-01-07 | — | — | CN | claimed |
| EP-4741018-A2 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-05-13 | — | — | EP | disclosed |
| US-12583836-B2 | Sulphonamide compounds | Anaxis Pharma Pty Ltd (AU) | 2026-03-24 | — | — | US | disclosed |
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | ACONCAGUA BIO INC (US) | 2026-03-12 | — | — | US | disclosed |
| US-12545684-B2 | CDK2 inhibitors | BLUEPRINT MEDICINES CORPORATION (US) | 2026-02-10 | — | — | US | disclosed |
| EP-4168401-B1 | SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2026-01-07 | — | — | EP | disclosed |
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PROGENTOS THERAPEUTICS, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-04-10 | — | — | US | disclosed |
| US-20250074891-A1 | BIFUNCTIONAL SULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-03-06 | — | — | US | disclosed |
| US-20250059188-A1 | ARYLSULPHONAMIDE COMPOUNDS | Anaxis Pharma Pty Ltd (AU) | 2025-02-20 | — | — | US | disclosed |
| CN-101180266-A | Alpha ketoamide compounds as cysteine protease inhibitors | APPLERA CORP (US) | 2008-05-14 | — | — | CN | disclosed |
| EP-1866276-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CELERA GENOMICS (US) | 2007-12-19 | — | — | EP | disclosed |
| CN-1894213-A | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives | MERCK & CO INC (CA) | 2007-01-10 | — | — | CN | disclosed |
| WO-2006102423-A1 | ALPHA KETOAMIDE COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS | CELERA GENOMICS (US) | 2006-09-28 | — | — | WO | disclosed |
| WO-2006046056-A1 | PROCESS FOR THE TRANSFER HYDROGENATION OF AN ORGANIC COMPOUND IN THE PRESENCE OF A CATALYST REGENERATOR | AVECIA PHARMACEUTICALS LIMITED (GB) | 2006-05-04 | — | — | WO | disclosed |
| US-7019022-B2 | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives | MERCK FROSST CANADA & CO. (CA) | 2006-03-28 | — | — | US | disclosed |
| US-20050154044-A1 | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives | MERCK FROSST CANADA LTD. (CA) | 2005-07-14 | — | — | US | disclosed |
| EP-1343760-A2 | MUSCARINIC ANTAGONISTS | Schering Corporation (US) | 2003-09-17 | — | — | EP | disclosed |
| US-6458812-B1 | KIT AND METHOD FOR COGNITION ACTIVATION | SCHERING CORPORATION | 2002-10-01 | — | — | US | disclosed |
| WO-2002051808-A2 | MUSCARINIC ANTAGONISTS | SCHERING CORPORATION (US) | 2002-07-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074891-A1 | BIFUNCTIONAL SULPHONAMIDE COMPOUNDS | MLKL, RIPK3, CASP9 | AOC3 4600/4885NOS3 542/4885NOS1 364/4885 |
| US-12583836-B2 | Sulphonamide compounds | MLKL, RIPK3, CASP1 | AOC3 4184/4885NOS3 246/4885NOS1 131/4885 |
| US-20250115598-A1 | BIFUNCTIONAL ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | AOC3 3087/4885NOS3 705/4885NOS1 516/4885 |
| US-20250129067-A1 | PLATELET-DERIVED GROWTH FACTOR RECEPTOR (PDGFR) ALPHA INHIBITORS AND USES THEREOF | PDGFRB, PDGFRA, PDGFA | AOC3 4165/4885NOS3 3846/4885NOS1 4240/4885 |
| US-20050154044-A1 | Substituted tetrahydrocarbazole and cyclopentanoindole derivatives | PTGIR, PTGDR, PTGDR2 | AOC3 1663/4885NOS3 662/4885NOS1 1143/4885 |
| US-12545684-B2 | CDK2 inhibitors | CDK2, CDK4, CDK1 | AOC3 3822/4885NOS3 4240/4885NOS1 4331/4885 |
| US-20250059188-A1 | ARYLSULPHONAMIDE COMPOUNDS | MLKL, CASP1, CASP9 | AOC3 3955/4885NOS3 264/4885NOS1 180/4885 |
| US-20260069602-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | SCTR, SSTR1, NPY1R | AOC3 616/4885NOS3 3363/4885NOS1 4008/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.